Availability
0
Your Basket is Empty
FA17899
BIO-X

Anacetrapib

A potent inhibitor of CETP that inhibits transfer of cholesteryl esters and triglycerides. Raises HDL cholesterol levels whilst lowering LDL cholesterol. Reduces cardiovascular events in patients with atherosclerotic vascular disease that receive statin treatment.

Technical Data

CAS No: 875446-37-0
Synonyms: (4S,5R)-5-[3,5-Bis(trifluoromethyl)phenyl]-3-[[4'-fluoro-2'-methoxy-5'-(1-methylethyl)-4-(trifluoromethyl)[1,1'-biphenyl]-2-yl]methyl]-4-methyl-2-oxazolidinone; (4S,5R)-5-[3,5-Bis(trifluoromethyl)phenyl]-3-[[4'-fluoro-5'-isopropyl-2'-methoxy-4-(trifluoromethyl)biphenyl-2-yl]methyl]-4-methyl-1,3-oxazolidin-2-one; MK 0859
Product Code: FA17899
MDL No: MFCD16294903
Chemical Formula: C30H25F10NO3
Molecular Weight: 637.51

References


  • Ranalletta M et al (2010). Biochemical characterization of cholesteryl ester transfer protein inhibitors. J Lipid Res 51(9):2739-52.
  • HPS3/TIMI55–REVEAL Collaborative Group et al (2017). Effects of Anacetrapib in Patients with Atherosclerotic Vascular Disease. N Engl J Med 377(13):1217-1227.
  • Filippatos TD et al (2017). Anacetrapib, a New CETP Inhibitor: The New Tool for the Management of Dyslipidemias? Diseases 5(4). pii: E21.

Solubility

Stability

Further Information


Datasheets

Specification: View
MSDS: View

CAS No:
875446-37-0
Synonyms:
(4S,5R)-5-[3,5-Bis(trifluoromethyl)phenyl]-3-[[4'-fluoro-2'-methoxy-5'-(1-methylethyl)-4-(trifluoromethyl)[1,1'-biphenyl]-2-yl]methyl]-4-methyl-2-oxazolidinone
(4S,5R)-5-[3,5-Bis(trifluoromethyl)phenyl]-3-[[4'-fluoro-5'-isopropyl-2'-methoxy-4-(trifluoromethyl)biphenyl-2-yl]methyl]-4-methyl-1,3-oxazolidin-2-one
MK 0859
MDL No:
MFCD16294903
Chemical Formula:
Molecular Weight:
637.51
Product Structure
References:
1. Ranalletta M et al (2010). Biochemical characterization of cholesteryl ester transfer protein inhibitors. J Lipid Res 51(9):2739-52.
2. HPS3/TIMI55–REVEAL Collaborative Group et al (2017). Effects of Anacetrapib in Patients with Atherosclerotic Vascular Disease. N Engl J Med 377(13):1217-1227.
3. Filippatos TD et al (2017). Anacetrapib, a New CETP Inhibitor: The New Tool for the Management of Dyslipidemias? Diseases 5(4). pii: E21.
Click for Specification
Click for MSDS

For requirements greater than the catalogue prepacks email: enquiries@carbosynth.com

Custom Synthesis

For custom synthesis or special requests email: enquiries@carbosynth.com, call +44 (0)1635 578444 or fill out our contact form

Please Wait...